274 related articles for article (PubMed ID: 35759511)
1. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.
Monath TP; Nichols R; Tussey L; Scappaticci K; Pullano TG; Whiteman MD; Vasilakis N; Rossi SL; Campos RK; Azar SR; Spratt HM; Seaton BL; Archambault WT; Costecalde YV; Moore EH; Hawks RJ; Fusco J
PLoS Pathog; 2022 Jun; 18(6):e1010658. PubMed ID: 35759511
[TBL] [Abstract][Full Text] [Related]
2. Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease.
Monath TP; Nichols R; Feldmann F; Griffin A; Haddock E; Callison J; Meade-White K; Okumura A; Lovaglio J; Hanley PW; Clancy CS; Shaia C; Rida W; Fusco J
Front Immunol; 2023; 14():1216225. PubMed ID: 37731485
[TBL] [Abstract][Full Text] [Related]
3. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.
DeBuysscher BL; Scott D; Marzi A; Prescott J; Feldmann H
Vaccine; 2014 May; 32(22):2637-44. PubMed ID: 24631094
[TBL] [Abstract][Full Text] [Related]
4. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
[TBL] [Abstract][Full Text] [Related]
5. Rhabdovirus-based vaccine platforms against henipaviruses.
Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
[TBL] [Abstract][Full Text] [Related]
6. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
Kasereka MC; Mumtaz Z; Hawkes MT
Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
[TBL] [Abstract][Full Text] [Related]
7. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.
Lo MK; Bird BH; Chattopadhyay A; Drew CP; Martin BE; Coleman JD; Rose JK; Nichol ST; Spiropoulou CF
Antiviral Res; 2014 Jan; 101():26-9. PubMed ID: 24184127
[TBL] [Abstract][Full Text] [Related]
8. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
[TBL] [Abstract][Full Text] [Related]
9. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
[No Abstract] [Full Text] [Related]
10. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
Mire CE; Miller AD; Carville A; Westmoreland SV; Geisbert JB; Mansfield KG; Feldmann H; Hensley LE; Geisbert TW
PLoS Negl Trop Dis; 2012; 6(3):e1567. PubMed ID: 22448291
[TBL] [Abstract][Full Text] [Related]
11. Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.
Watanabe S; Yoshikawa T; Kaku Y; Kurosu T; Fukushi S; Sugimoto S; Nishisaka Y; Fuji H; Marsh G; Maeda K; Ebihara H; Morikawa S; Shimojima M; Saijo M
PLoS Negl Trop Dis; 2023 Dec; 17(12):e0011851. PubMed ID: 38100536
[TBL] [Abstract][Full Text] [Related]
12. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
[TBL] [Abstract][Full Text] [Related]
13. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.
Saito T; Maruyama J; Nagata N; Isono M; Okuya K; Takadate Y; Kida Y; Miyamoto H; Mori-Kajihara A; Hattori T; Furuyama W; Ogawa S; Iida S; Takada A
Viruses; 2020 Aug; 12(9):. PubMed ID: 32842671
[TBL] [Abstract][Full Text] [Related]
14. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
15. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
Foster SL; Woolsey C; Borisevich V; Agans KN; Prasad AN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Cross RW; Geisbert TW
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2200065119. PubMed ID: 35286211
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
Locher S; Schweneker M; Hausmann J; Zimmer G
J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
[TBL] [Abstract][Full Text] [Related]
17. Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells.
Hoffmann M; Nehlmeier I; Brinkmann C; Krähling V; Behner L; Moldenhauer AS; Krüger N; Nehls J; Schindler M; Hoenen T; Maisner A; Becker S; Pöhlmann S
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429347
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
[TBL] [Abstract][Full Text] [Related]
19. A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.
Woolsey C; Strampe J; Fenton KA; Agans KN; Martinez J; Borisevich V; Dobias NS; Deer DJ; Geisbert JB; Cross RW; Connor JH; Geisbert TW
J Infect Dis; 2023 Nov; 228(Suppl 7):S712-S720. PubMed ID: 37290053
[TBL] [Abstract][Full Text] [Related]
20. Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model.
de Wit E; Feldmann F; Cronin J; Goldin K; Mercado-Hernandez R; Williamson BN; Meade-White K; Okumura A; Callison J; Weatherman S; Rosenke R; Avanzato VA; Lovaglio J; Scott DP; Marzi A; Feldmann H
EBioMedicine; 2023 Jan; 87():104405. PubMed ID: 36508878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
